Search

Search Constraints

You searched for: Author/Creator Butt, Thomas

Search Results

13. The cost-effectiveness of initiating ranibizumab therapy in eyes with neovascular AMD with good vision: an economic model using real-world outcomes. Issue 5 (5th May 2015)

14. The economics of vision impairment and its leading causes: A systematic review. (April 2022)

15. UK AMD EMR USERS GROUP REPORT V: benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6/12. Issue 8 (13th February 2015)

16. VP175 Validating Outcome Assessments For Health Technology Assessment In Ceroid Lipofuscinosis Neuronal 2 (CLN2), An Ultra-Rare Disease. (12th January 2018)

17. VP175 Validating Outcome Assessments For Health Technology Assessment In Ceroid Lipofuscinosis Neuronal 2 (CLN2), An Ultra-Rare Disease. (2017)